Abstract:Introduction: Novel compounds targeting various aspects of fibrogenesis have been developed consequent to the increasing knowledge of the pathogenetic mechanisms of the interstitial lung diseases (ILDs). The authors review the evolution of treatment approaches in the ILDs, informed by recent placebo-controlled trials, and discuss current clinical trials in which emerging pathogenetic mechanisms are targeted as novel therapeutic agents. Areas covered: In idiopathic pulmonary fibrosis (IPF), recent randomised, placebo-controlled trials have tested the efficacy of new therapies, and although primary end points have not been met in most, treatment effects have been observed. The demonstration of harmful effects from widely used IPF therapies has been equally important. Pirfenidone and nintedanib are emerging agents that exert pleiotropic effects, reflective of the multiple mechanistic pathways of IPF. Treatment may necessitate a similarly multifaceted approach using combination regimens of antifibrotic and antioxidant agents in order to be effective. In other ILDs, including systemic sclerosis, other connective tissue diseases and pulmonary sarcoidosis, the inflammatory/fibrotic model remains appropriate. Studies in systemic sclerosis have provided 'proof of concept' data for immunosuppressive therapy in the prevention of disease progression but there is a continuing need for controlled clinical trials in the more prevalent ILDs. Expert opinion: In IPF, significant treatment effects have been reported with pirfenidone, nintedanib and N-acetylcysteine. Combinations of these pleiotropic agents, along with future monotherapies, in 'oncological regimens' may hold the key to more effective IPF treatment. In disorders other than IPF, there is an ongoing need for the controlled evaluation of traditional anti-inflammatory and immunosuppressive therapies. 'Cohort enrichment' (the selective recruitment of patients most likely to progress) holds the key to the identification of worthwhile treatment benefits.

The dawn of precision medicine in fibrotic interstitial lung disease

Precision medicine advances in idiopathic pulmonary fibrosis

A roadmap to precision treatments for familial pulmonary fibrosis

Genomic Profiling for Predictive Treatment Strategies in Fibrotic Interstitial Lung Disease

Advances in Targeted Therapy for Progressive Fibrosing Interstitial Lung Disease

The role of precision medicine in interstitial lung disease

Pathological mechanisms and novel drug targets in fibrotic interstitial lung disease

Current Challenges and Novel Therapeutic Perspectives

The evolving pharmacotherapy of pulmonary fibrosis

Progress in understanding and treating idiopathic pulmonary fibrosis: recent insights and emerging therapies

Progression of fibrosing interstitial lung disease

Challenges for Clinical Drug Development in Pulmonary Fibrosis

Fibrosing interstitial lung diseases: knowns and unknowns

Highlights on Future Treatments of IPF: Clues and Pitfalls

Fibrotic Idiopathic Interstitial Lung Disease: The Molecular and Cellular Key Players

Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs)

Pulmonary fibrosis: Emerging diagnostic and therapeutic strategies

Molecular Biomarkers in Idiopathic Pulmonary Fibrosis: State of the Art and Future Directions

Diagnosis and Management of Fibrotic Interstitial Lung Diseases

Immune mechanisms in fibrotic interstitial lung disease

Pursuing Clinical Predictors and Biomarkers for Progression in ILD: Analysis of the Pulmonary Fibrosis Foundation (PFF) Registry